Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Inclusion Criteria

• •1. Male or female patient with histologically proven cutaneous melanoma. Phase I segment: All melanoma patients with stage IV M1b and stage IV M1c including completely resected stage IV patients but with the exception of stage IV M1c disease with serum lactate dehydrogenase \> 1.5 x Upper Limit of Normal or with involvement of the Central Nervous System.
• •Phase II segment: All melanoma patients with measurable, unresectable stage III melanoma including in-transit metastasis (with (N3) or without (N2c) nodal metastasis) and stage IV M1a melanoma. The patient should have documented progressive disease within 12 weeks of registration into the trial. Patients with resected stage IV and with stage IV M1b or M1c disease cannot be included.
• •2. Written informed consent for PRAME expression screening and gene profiling on resected tumor tissue and for the complete study has been obtained from the patient prior to shipment of the sample for expression testing and prior to the performance of any other protocol-specific procedure.
• •3. The patient is \>= 18 years old at the time of signing the first informed consent form.
• •4. The patient's tumor shows expression of the PRAME antigen as determined by RT-PCR analysis or any updated technique on fresh tissue sample.
• •5. Eastern Cooperative Oncology Group performance status of 0 or 1.
• •6. The patient has adequate bone marrow reserve, renal, adrenal and hepatic function as assessed by standard laboratory criteria.
• •7. Female patients of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.
• •8. Female patients of childbearing potential may be enrolled in the study, if the patient:
• •* has practiced adequate contraception for 30 days prior to the study product administration, and
• •* has a negative pregnancy test on the day of administration, and
• •* has agreed to continue adequate contraception during the entire treatment period and for 2 months after the completion of the study product administration series.
• •9. In the view of the investigator, the patient can and will comply with all the requirements of the protocol.